Pharvaris' Deucrictibant Shows Rapid Efficacy in HAE Treatment

Event summary

  • Pharvaris presented data at EAACI 2026 showing deucrictibant's rapid efficacy in treating HAE attacks, with median time to symptom relief of 1.28 hours vs. over 12 hours with placebo.
  • RAPIDe-3 study demonstrated 83% of attacks treated with a single capsule of deucrictibant, with no treatment-related serious adverse events.
  • Long-term prophylaxis data from CHAPTER-1 showed a 92% reduction in HAE attack rates, with participants treated for up to ~34 months.
  • Cardiovascular safety analysis across ~570 participants showed no evidence of QT prolongation or clinically meaningful cardiac risks.

The big picture

Pharvaris' data at EAACI 2026 underscores the potential of deucrictibant to disrupt the HAE treatment landscape with its oral administration, rapid onset, and sustained efficacy. The company's focus on both on-demand and prophylactic settings aligns with the broader industry shift towards more convenient and effective therapies for rare diseases. The upcoming regulatory decisions and clinical milestones will be critical in determining deucrictibant's market positioning and commercial potential.

What we're watching

Regulatory Pathway
Whether Pharvaris can secure marketing authorization for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks by the first half of 2026.
Clinical Validation
The pace at which deucrictibant extended-release tablet demonstrates sustained efficacy in the ongoing CHAPTER-3 Phase 3 study, with topline data anticipated in Q3 2026.
Market Differentiation
How Pharvaris positions deucrictibant against existing injectable treatments and emerging therapies in the bradykinin-mediated angioedema space.